X Square Capital LLC Sells 7,825 Shares of OPKO Health, Inc. (NASDAQ:OPK)

X Square Capital LLC decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 4.6% during the 4th quarter, Holdings Channel.com reports. The fund owned 161,726 shares of the biotechnology company’s stock after selling 7,825 shares during the quarter. X Square Capital LLC’s holdings in OPKO Health were worth $238,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of OPK. Norges Bank bought a new position in shares of OPKO Health in the fourth quarter valued at $1,657,000. Clearline Capital LP bought a new stake in shares of OPKO Health during the 3rd quarter valued at about $1,083,000. Essential Planning LLC. purchased a new stake in OPKO Health in the fourth quarter worth approximately $506,000. Barclays PLC boosted its stake in shares of OPKO Health by 154.5% during the third quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock valued at $810,000 after purchasing an additional 329,870 shares during the period. Finally, BNP Paribas Financial Markets raised its position in OPKO Health by 736.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 217,450 shares during the last quarter. Institutional investors and hedge funds own 64.63% of the company’s stock.

Insider Transactions at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 150,000 shares of the firm’s stock in a transaction dated Friday, January 17th. The stock was acquired at an average cost of $1.47 per share, with a total value of $220,500.00. Following the acquisition, the chief executive officer now owns 213,186,477 shares of the company’s stock, valued at approximately $313,384,121.19. This represents a 0.07 % increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders bought a total of 964,971 shares of company stock worth $1,493,692 over the last ninety days. 47.26% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Barrington Research reissued an “outperform” rating and set a $2.25 price target on shares of OPKO Health in a research report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a research note on Wednesday, March 19th. Finally, StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Monday, March 3rd.

OPKO Health Stock Down 1.7 %

OPK opened at $1.74 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The company has a 50-day moving average price of $1.68 and a 200 day moving average price of $1.58. OPKO Health, Inc. has a twelve month low of $1.12 and a twelve month high of $2.04. The company has a market cap of $1.17 billion, a PE ratio of -9.16 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Sell-side analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current fiscal year.

OPKO Health Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.